Back
Biotherapeutics company Prellis Bio appoints new CEO, raises $35M series C
Back
Avatar
Hannah DeTavis

Biotherapeutics company Prellis Biologics (IndieBio SF05 2017) has appointed Michael Nohaile, PhD as its new CEO, according to a Business Wire press release, “Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development”

Prellis Biologics CEO Michael Nohaile, PhD
Prellis Biologics CEO Michael Nohaile, PhD. Source: Business Wire

The company also announced a $35 million in a series C funding round, co-led by Avidity Partners and Celesta Capital. The funding round received support from SOSV, Khosla Ventures, True Ventures, and Lucas Venture Group—bringing Prellis Biologics total funding to date to $64.5 million, Business Wire reports.

Prellis Bio’s industry-leading two-photon holographic technology supports 3D printing of large, complex tissue co-culture systems, such as LNOsTM (Lymph Node Organoids) that recapitulate human immune responses in vitro. The EXIS platform incorporates LNOs for the discovery of fully human antibodies with broad genetic diversity in as little as three to four weeks. In addition, EXIS enables assessment of immunogenicity in response to therapeutic candidates.

“The LNO technology represents a significant breakthrough in access to human immunobiology. Previously, immune cells were expected to respond without the biological context of a functional lymph node,” said Dr. Melanie Matheu, the founder of Prellis. “With 3D printed LNOs, we have the opportunity to accelerate drug discovery and development, while acquiring data on human immune responses all outside of the context of a clinical trial.”

Dr. Nohaile joins from Generate Biomedicines and succeeds Dr. Matheu, who will assume the role of Chief Technology Officer and retain a Board seat. Dr. Nohaile brings deep industry experience and expertise in leveraging innovative technologies for therapeutic discovery and development. Prior to his role as Chief Scientific Officer of Flagship company Generate Biomedicines, he was SVP of Strategy, Commercialization, and Innovation at Amgen, and Global Head of Molecular Diagnostics at Novartis.

“I am honored to join the Prellis Bio team and to partner with Melanie and the entire Prellis team to further build on their inspiring vision for the next generation of medicines,” Dr. Nohaile said in the press release. “This new chapter and investment will enable our team to bring better medicines to patients who desperately need them.”

Did you know?